In a report issued on January 27, Joanne Wuensch from BMO Capital reiterated a Buy rating on Resmed Inc (RMD), with a price target of $120. The company’s shares closed yesterday at $92.04, close to its 52-week low of $87.67.
According to TipRanks.com, Wuensch is a 5-star analyst with an average return of 12.1% and a 69.9% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Baxter International, Wright Medical Group, and Johnson & Johnson.
The word on The Street in general, suggests a Hold analyst consensus rating for Resmed Inc with a $103.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $118.50 and a one-year low of $87.67. Currently, Resmed Inc has an average volume of 1.02M.
Based on the recent corporate insider activity of 106 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ResMed, Inc. engages in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. Its product portfolio includes devices, diagnostic products, mask systems, headgear and other accessories, and dental devices. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.
Read More on RMD:
